Patients experienced a 38% reduction in the risk of disease progression or death when treated with Opdivo plus Yervoy versus Opdivo monotherapy across all lines of therapy at median 47 months of follow-up Late-breaking data presented in oral session at the 2025
WEST HARRISON, N.Y. — (BUSINESS WIRE) — Sky Harbour Group Corporation (NYSE American: SKYH, SKYH WS) (“SHG” or the “Company”), an aviation infrastructure company building the first nationwide network of Home-Basing campuses for business aircraft, announced on Saturday that the Company will
MOUNT LAUREL, N.J. — (BUSINESS WIRE) — 1st Colonial Bancorp, Inc. (FCOB), holding company of 1st Colonial Community Bank, today announced that its board of directors has approved a stock repurchase program, effective Jan. 30, 2025. Under the stock repurchase program,
– Premiere law firm secured hallmark $44 M settlement, expanded nationwide with new offices in Ohio and Kentucky, and introduced new practice areas RIVER EDGE, N.J. — (BUSINESS WIRE) — Brandon J. Broderick, a leading law firm dedicated to providing
PARSIPPANY, N.J. — (BUSINESS WIRE) — YARAL Pharma Inc. (YARAL Pharma), the U.S. generics subsidiary of IBSA (Institut Biochimique SA), a multinational pharmaceutical company headquartered in Lugano, Switzerland, today announced that it will continue working with the Pharmacy Podcast Network (PPN), a
Hezi Saar of Synopsys appointed board chair; new vice chair and treasurer named for global organization developing interface specifications for mobile, IoT, automotive and related industries BRIDGEWATER, N.J. — (BUSINESS WIRE) — #IoT — The MIPI Alliance, an international organization
OLDWICK, N.J. — (BUSINESS WIRE) — #insurance — AM Best will host an analytical briefing to discuss global reinsurance market conditions and the Jan. 1 renewal season on Thursday, Jan. 30, 2025, at 10 a.m. EST. AM Best Senior Associate Editor John
First approval in the U.S. for Daiichi Sankyo and AstraZeneca’s DATROWAY based on TROPION-Breast01 results showing 37% reduction in the risk of disease progression or death versus chemotherapy Second DXd antibody drug conjugate approved in U.S. based on Daiichi Sankyo’s DXd technology
Revenue grows 0.1% QoQ, above upper end of guidance. Operating margin 12 quarter high at 17.5%; Expands 0.7% QoQ. Net income grows 24.5% YoY and 4.5% QoQ; EPS growth of 24.4% YoY. Operating cash flows at 146.5% of net income.